PRESS RELEASE – Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound

Dallas-Fort Worth (PRWEB) August 28, 2015 – Riordan-McKenna Institute founders, stem cell expert Neil Riordan, PhD and orthopedic surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by Amniotic Therapies in Dallas, Texas, resulted in complete healing of an otherwise non-healing surgical knee wound.

Before-After.262x175The case involved a 78-year-old male, who presented with a non-healing surgical wound following a right total knee replacement performed six weeks prior. The patient had not responded after 6 weeks of conservative wound care and the wound showed no signs of healing.

Dr. McKenna irrigated the wound in the operating room under pulse lavage and then placed two AlphaPATCH dry amniotic membranes (4 cm x 4 cm) over the wound before dressing it.

At the two-week follow-up visit, a central scab had formed. At four-weeks, the wound had completely scabbed over. At eight-weeks the scab had just fallen off and the wound was healing well with immature skin representing the size of a penny. At the ten-week follow-up visit, the wound was completely healed.

The case report, entitled “Case Report Of Non-Healing Surgical Wound Treated With Dehydrated Amniotic Membrane” is published in the July issue of the Journal of Translational Medicine. Authors include Dr. Riordan, Dr. McKenna, Troy Chandler, PA-C, and Ben George, PA-C. This milestone in Dr. Riordan and Dr. McKenna’s ongoing study of biologic wound healing using amniotic tissue products and stem cells is the third peer reviewed journal article on regenerative medicine published by the Riordan McKenna Institute.

A common misconception is that dehydrated amniotic membrane products like AlphaPATCH contain live stem cells. Although dehydrated amniotic membrane does not contain any stem cells, it does contain a number of growth factors that promote healing and stimulate the body’s own stem cells to become activated and likely behave more similar to stem cells in a younger person.

“It’s gratifying to have this new tool in my toolbox. I treated conservatively and was getting nowhere. Even in a patient with a significant smoking history and decreased blood flow to his legs, we were able to achieve this result. Chronic wounds can be very frustrating for both the patient and the caregiver,” remarked Troy Chandler, PA-C, who participated in the patient’s treatment.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.

BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

www.rmiclinic.com

801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

About Amniotic Therapies

Based in Dallas, Texas, Amniotic Therapies specializes in the processing and distribution of human amniotic tissue products for the biologic and regenerative medicine segments of the healthcare market. Amniotic Therapies’ mission is to provide superior human amniotic tissue products that naturally enhance the body’s healing ability, providing patients with improved healing.

Amniotic Therapies is registered with the U.S. Food and Drug Administration (FDA) and is in the process of receiving accreditation from the American Association of Tissue Banks.

www.amniotictherapies.com

11496 Luna Rd. Suite 800
Dallas, Texas
75235

Tel: (972) 465-0496

Colton’s walking after stem cell therapy for cerebral palsy in Panama

Colton is planning on coming to Panama for follow-up treatment later this year. Here is a video of him walking from June 2015.

And here was Colton in 2014 about one year prior to the video above. This video was taken a year after his first treatments in 2013.

To keep up with Colton’s progress on Facebook, please visit: https://www.facebook.com/ColtonMittmanFundraiser

Duchenne’s Patient Ryan Benton Discusses His Experience with Stem Cell Therapy

Ryan Benton is the first patient in the United States to receive human umbilical cord-derived mesenchymal stem cell therapy for Duchenne’s muscular dystrophy. The US FDA granted Ryan this trial under compassionate use. Ryan first began treatments at the Stem Cell Institute in Panama before being able to receive treatments in his hometown of Wichita, Kansas.

Inside High School Football Report on Hall of Fame Coach and Stem Cell Recipient, Sam Harrell

Sam, who suffers from multiple sclerosis, was forced to retire as Ennis (Texas) High School’s head football coach due to his debilitating symptoms. Sam’s first two treatments using stem cells harvested from his own fat did not yield long lasting, positive results. However, after his third and fourth trips to the Stem Cell Institute in Panama for umbilical cord tissue-derived mesenchymal stem cells, Sam’s life turned around. Now, Sam is back in the game again!

Stem Cell Therapy for Multiple Sclerosis: Ron McGill

Ron McGill suffers from relapsing-remitting multiple sclerosis. He was started experiencing symptoms in 2009 but was not diagnosed with MS until January of 2013. He received several infusion and injections of human umbilical cord-tissue derived stem cells at the Stem Cell Institute in late October and Early November 2013.

In this video, Ron shares his story of discovery and recovery at a Stem Cell Institute seminar in San Antonio in October 2014.

For more information on MS therapy at the Stem Cell Institute in Panama, please visit: https://www.cellmedicine.com/stem-cell-therapy-for-multiple-sclerosis-3/

Good afternoon.

I was diagnosed with relapsing-remitting MS in January of 2013. My symptoms started with tingling and numbness in my hands and feet migraine headaches in April, 2009. Visits to the doctors concluded that job stress-related migraines were all it was.

My high tolerance for pain accepted the results and I went on with life. This was an extremely poor decision on my part. My symptoms remained constant but non-progressing until November of 2011. In attempting to kick a soccer ball, I lost my balance and I fell. I wrote it off as being out of shape and clumsy. A fall on a treadmill and down a stairwell in early 2012 was my final wakeup call. It solidified that there was more wrong with me than normal.

My quest to find out what was causing my issues and how to resolve them was started.

Starting from behind and (inaudible) to catch up, I did several things. I made immediate dietary changes. Sodas, fast food, canned food, alcohol – eliminated. Red meat, dairy, bread, pasta – reduced drastically. Chicken, fish, fresh fruits, vegetables – doubled. I went on a weight loss and body detox regimen. I replaced impact aerobic exercises I could no longer do with swimming.

I made the most of my insurance. I literally became a human pin cushion. Everybody was sticking me. I looked outside traditional medicine: acupuncturist, building my immune system and pure vitamin regimens. While I made great strides in changing my life, I was testing healthier, a progression of worse symptoms continued to happen. Severe leg and back aches, leg stingers, twitching, lost grip and more loss of balance.

It was determined that MS was my cause. My instability had me falling one to two times a month. I reached my lowest point waking up immobile from the waist down on a Wednesday morning in February of 2013.

With my motor skills seemingly erased from my memory, a deep cloud of panic overtook me. My confidence went out the window. I had to dig down extremely deep. I was able to regain mobility later that evening. I progressed to a penguin walk and very limited speed and distance over the next 6 months with the help of a walking stick and physical therapy.
Hours of online research for possible relief led to stem cell therapy.

After many months of research, doctor consultations, numerous conversations with people who had had stem cell therapy, heard about it, had relatives who had experienced it, I sent the email to the Stem Cell Institute.

After being accepted, I still had more conversations with Dr. Barnett and Cindy, asking more and more questions. They were extremely patient to everything I had.

The care provided for me upon my arrival and during my stay and departure in Panama was extremely good. The facility was simple, clean, efficient with a very helpful and friendly staff. The procedure was well-explained to me and carefully administered.

I was able to see results on my way back (on) November 3rd. I was able to walk farther and feel better. I was able to my walking stick in the back of my car for good two weeks later. Knock on wood, I haven’t fallen since October 23rd of 2013. My stamina, walking speed and stability have continued to increase. I do have momentary balance loss and heat can still wipe me out. My MS is still with me.

Do I feel (that) Panama was the right choice? For me, absolutely. I feel the infusion of healthy cells gave my body a huge boost to recover the majority of lost motor skills I had experienced. It also helped amplify the lifestyle changes I was already making to give me a faster and more positive result.

These successes have given me a more positive mental state that have allowed me to heal more and more.

What advice could I give you about stem cells? Research, research, research. There isn’t a price you can put on due diligence when it comes to your health. Make lifestyle changes at the cellular level in your body and amplify it with stem cell therapy.

In closing, I’d like to thank my wife for undying support and hours of research. I’d like to thank Dr. Riordan, (and) Stem Cell Institute for being at the cutting edge of healing diseases and I’d like to thank you all for allowing me to share with you today.

Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase

Chicago, Illinois (PRWEB) October 30, 2014

On October 26th at the Mid American Regenerative and Cellular Medicine Showcase in Chicago, leading applied stem cell research scientist Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna presented talks on New Techniques for Enhancing Stem Cell Therapy Effectiveness and Orthopedic Surgical Applications For Stem Cells.

Dr. Riordan focused on historical medical uses of amniotic membrane and the properties of AlphaGEMS that include: wound healing; inflammation and pain reduction; fibrosis risk reduction; growth factor source; adhesion reduction; regeneration support and stem cell enhancement, specifically regarding the mesenchymal stem cells contained within BMAC.

Dr. McKenna discussed the latest applications of BMAC stem cells in orthopedic surgeries like anterior cruciate ligament (ACL) reconstruction and how BMAC injections can virtually eliminate infection risk, reduce complications, increase graft strength, reduce post-surgical inflammation and significantly reduce recovery time. Dr. McKenna also talked about how bone marrow can now be safely and relatively painlessly harvested using his patented BioMAC catheter under local, not general anesthesia.

Dr. Riordan and Dr. McKenna are co-founders of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Other noteworthy speakers in attendance included: Paolo Macchiarini, MD-PhD, Arnold Caplan, PhD and Mark Holterman, MD-PhD. Dr. Macchiarini and Dr. Holterman are well known for their work on the first stem cell trachea transplant. Dr. Caplan discovered the mesenchymal stem cell and is commonly referred to as the father of the mesenchymal stem cell.

About Neil Riordan PhD

Dr. Riordan is the co-founder of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Dr. Riordan is founder and chief scientific officer of Amniotic Therapies Inc. (ATI). ATI specializes in amniotic tissue research and development. Its current product line includes AlphaGEMS and AlphaPATCH amniotic tissue-based products.

Dr. Riordan is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI’s stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).

Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting five IRB-approved clinical trials in Panama for multiple sclerosis, rheumatoid arthritis and osteoarthritis using human umbilical cord-derived mesenchymal stem cells, mesenchymal trophic factors and stromal vascular fraction. Additional trials for spinal cord injury, autism and cerebral palsy are slated to commence in 2014 upon IRB approval.

Dr. Riordan is an accomplished inventor; listed on more the 25 patent families, including 11 issued patents. He is credited with a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr. Hugh Riordan on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin Cs preferential toxicity to cancer cells notably led to a 1997 patent grant for the treatment of cancer with vitamin C. In 2010, Dr. Riordan received another patent for a new cellular cancer vaccine.

Dr. Riordan is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals including Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.

Dr. Riordan earned his Bachelor of Science at Wichita State University and graduated magna cum laude. He received his Masters degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the Americas.

About Dr. Wade McKenna

Dr. Wade McKenna is cofounder of the Riordan-McKenna Institute. He is a leading advocate of Autologous Stem Cell Therapy and Regenerative Medicine focusing on advancing the clinical benefits in orthopedics.

Board certified in orthopedic surgery, Dr. McKenna is the chief medical officer and co-founder of Biologic Therapies, a product development and research company dedicated to the advancement of autologous adult stem cell therapy. His achievements include the recent development of the BioMac bone marrow aspiration catheter, treating world-class athletes, and developing numerous surgical and non-surgical stem cell application protocols.

After receiving his undergraduate degree and earning his medical degree at Oklahoma State University, Dr. McKenna completed his orthopedic residency at the Dallas/Ft Worth Medical Center and his trauma fellowship at Tampa General Hospital. With over 20 years in private practice, Dr. McKenna has successfully built McKenna Orthopedics in Trophy Club, Texas and North Central Texas Orthopedics & Sports Medicine in Decatur, Texas.

Dr. McKenna has a proven track record of producing positive clinical outcomes augmented by concentrated, autologous bone marrow aspirate. Dr. McKenna has applied this stem cell-enriched product to thousands of surgical and non-surgical patients. Successful applications include long bone non-unions; avascular necrosis of the femoral head; severe clavicle non-unions; cartilage regeneration; chondrogenesis and soft tissue repair of the shoulder; chronic tendonopathy; tendon ruptures; numerous applications to common, often difficult foot and ankle injuries; and wrists fractures.

Riordan-McKenna Institute
www.rmiclinic.com
801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

Neil Riordan, PhD Presents at American Academy of Anti-Aging Medicine’s 22nd Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine in Orlando, May 15

Neil Riordan, PhD will Present “Umbilical Cord Mesenchymal Stem Cells in the Treatment of Autoimmune Diseases” at the 22nd Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine at the Gaylord Palms Hotel in Orlando, Florida as part of the Specialty Workshop: “Stem Cells in Anti-Aging Medicine: An Update”.

Orlando, FL (PRWEB) May 13, 2014

Neil Riordan, PhD will Present “Umbilical Cord Mesenchymal Stem Cells (MSC) in the Treatment of Autoimmune Diseases” at the 22nd Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine at the Gaylord Palms Hotel in Orlando, Florida as part of the Specialty Workshop: “Stem Cells in Anti-Aging Medicine: An Update”.

The primary focus of this workshop is to teach medical professionals how to successfully incorporate stem cell treatments into their practices. Expert faculty will cover stem cell theory and clinical trial research for all aspects of regenerative medicine as well as stem cell treatment marketing.

Dr. Riordan will discuss: Allogeneic mesenchymal stem cells’ mechanisms of immune modulating activities; the importance of MSC placement for clinical effect; human clinical trials demonstrating efficacy; alternative routes of MSC delivery; dose and frequency; and clinical safety of MSC.

The conference will be held from May 15 – 17, 2014 at the Gaylord Palms Hotel in Orlando, Florida. For more information, please visit http://www.a4m.com/anti-aging-conference-orlando-2014-may.html.

About Neil Riordan PhD
Dr. Riordan is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI’s stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).

Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting five IRB-approved clinical trials in Panama for multiple sclerosis, rheumatoid arthritis and osteoarthritis using human umbilical cord-derived mesenchymal stem cells, mesenchymal trophic factors and stromal vascular fraction. Additional trials for spinal cord injury, autism and cerebral palsy are slated to commence in 2014 upon IRB approval.

Dr. Riordan is an accomplished inventor listed on more than 25 patent families, including 11 issued patents. He is credited with a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr. Hugh Riordan on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin C’s preferential toxicity to cancer cells notably led to a 1997 patent grant for the treatment of cancer with vitamin C. In 2010, Dr. Riordan received another patent for a new cellular cancer vaccine.

Dr. Riordan is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals including Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.

Dr. Riordan earned his Bachelor of Science at Wichita State University and graduated magna cum laude. He received his Master’s degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the Americas.

About Stem Cell Institute Panama
Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute (SCI) has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor human umbilical cord stem cells to treat: multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases.

In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for osteoarthritis, rheumatoid arthritis, and multiple sclerosis using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC), autologous stromal vascular fraction (SVF) and hU-MSC-derived mesenchymal trophic factors (MTF). In 2014, Translation Biosciences expects to expand its clinical trial portfolio to include spinal cord injury, heart disease, autism and cerebral palsy.

For more information on stem cell therapy:

Stem Cell Institute Website: http://www.cellmedicine.com

Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama

About Medistem Panama Inc.

Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.

Medistem Panama Inc.
Ciudad del Saber, Edif. 221 / Clayton
Panama, Rep. of Panama

Phone: +507 306-2601
Fax: +507 306-2601

Web site: http://www.medistempanama.com

About Translational Biosciences
A subsidiary of Medistem Panama Inc., Translational Biosciences was founded solely to conduct clinical trials using adult stem cells and adult stem cell-derived products.

Translational Biosciences Web Site: http://www.translationalbiosciences.com

Multiple sclerosis patient retires his walking stick after umbilical cord-derived stem cell therapy

From: mcgillron
Date: Wed, Nov 27, 2013 at 11:51 AM
Subject: Happy Thanksgiving!
To: edited_for_privacy@cellmedicine.com

Dr Barnett / Dr Hernandez & all staff at Clinic,

It’s a very special Thanksgiving for my household & I owe it to the efforts of all of you!

I’ve been walking without my stick since returning from stem cell therapy. 1 week of holding it for security & going on 3rd week of it riding in truck of my car. My stability is becoming more consistent & controlled. I am walking farther longer, riding bicycle more rhythmic & swimming smoother strokes.

Results are much greater than I expected. I believe the lifestyle changes, vitamin regimen, herbals, exercise & positive attitude adopted 14 months prior to visiting you allowed me to receive maximum benefit from the stem cell therapy.

I look forward to progressing my abilities back to a higher level over the next months.

If you would like me to share what I’ve done & am doing to get my results, feel free to give my email.

Dr Hernandez – please stay in contact on the herbal adjustments I’m making to solve final 2 deficiencies.

THANKS AGAIN for your hospitality & care!

Ron Mc Gill

Stem Cell Therapy for spinal cord injury: Theo Kostoulas

Theo Kostoulas is a T-6 complete spinal cord injury patient. He received a course of 16 stem cell therapy injections using umbilical cord-derived stem cells and his own bone marrow-derived stem cells. The cells were injected both intravenously and intrathecally (into the spinal fluid). During his stay in Panama and as part of his treatment protocol, Theo went to 19 physical therapy sessions over the course of month.

“I can definitely say that after the second injection, I immediately actually started getting some leg sensation and touch back from below my injury level. It was me lying in bed while my mother was putting my sock on my feet. I was actually able to feel that and it was pretty amazing because I haven’t had and feeling or sensation at all from my injury level of T-6. Now, more towards the end here, I have actually been able to have bladder sensation. I am a person that usually cath’ed myself every four hours but now because I do have this sensation coming back, I tend to wait until I have the need to have to go. So it can be anywhere from six to seven hours. If I need to drink a lot of water before coming to treatment, I know ahead of time whether I need to cath myself sooner or not.”

The dual effect of MSCs on tumour growth and tumour angiogenesis

Michelle Kéramidas, Florence de Fraipont, Anastassia Karageorgis, Anaïck Moisan, Virginie Persoons, Marie-Jeanne Richard, Jean-Luc Coll and Claire Rome

Abstract (provisional)
Introduction

Understanding the multiple biological functions played by human mesenchymal stem cells (hMSCs) as well as their development as therapeutics in regenerative medicine or in cancer treatment are major fields of research. Indeed, it has been established that hMSCs play a central role in the pathogenesis and progression of tumours, but their impact on tumour growth remains controversial.

Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.

Methods

In this study, we investigated the influence of hMSCs on the growth of pre-established tumours. We engrafted nude mice with luciferase-positive mouse adenocarcinoma cells (TSA-Luc+) to obtain subcutaneous or lung tumours. When tumour presence was confirmed by non-invasive bioluminescence imaging, hMSCs were injected into the periphery of the SC tumours or delivered by systemic intravenous injection in mice bearing either SC tumours or lung metastasis.

Results

Regardless of the tumour model and mode of hMSC injection, hMSC administration was always associated with decreased tumour growth due to an inhibition of tumour cell proliferation, likely resulting from deep modifications of the tumour angiogenesis. Indeed, we established that although hMSCs can induce the formation of new blood vessels in a non-tumoural cellulose sponge model in mice, they do not modify the overall amount of haemoglobin delivered into the SC tumours or lung metastasis. We observed that these tumour vessels were reduced in number but were longer.

Conclusions

Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.

Original Link: http://stemcellres.com/content/4/2/41/abstract